CR20200114A - Compuestos que contienen pirazolopirimidinona y sus usos - Google Patents

Compuestos que contienen pirazolopirimidinona y sus usos

Info

Publication number
CR20200114A
CR20200114A CR20200114A CR20200114A CR20200114A CR 20200114 A CR20200114 A CR 20200114A CR 20200114 A CR20200114 A CR 20200114A CR 20200114 A CR20200114 A CR 20200114A CR 20200114 A CR20200114 A CR 20200114A
Authority
CR
Costa Rica
Prior art keywords
compounds
relates
present
pyrazolopyrimidinone
pharmaceutical compositions
Prior art date
Application number
CR20200114A
Other languages
English (en)
Inventor
Stephane Ciblat
Chudi Obioma Ndubaku
Mariam Zaky
Laura Gillard
Vu Linh Ly
Yeeman K Ramtohul
George Edwin Katibah
Tucker Curran Roberts
Leonard Sung
Franck Raeppel
Hossein Ismaili
Taras Rybak
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of CR20200114A publication Critical patent/CR20200114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolopirimidinona. La presente invención también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar enfermedades autoinmunitarias, inflamatorias y neurodegenerativas mediante la administración de estos compuestos y composiciones farmacéuticas a sujetos que los necesitan. La presente invención también se refiere al uso de tales compuestos para investigación u otros fines no terapéuticos
CR20200114A 2017-09-15 2018-09-14 Compuestos que contienen pirazolopirimidinona y sus usos CR20200114A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762559482P 2017-09-15 2017-09-15
US201862633248P 2018-02-21 2018-02-21
US201862687769P 2018-06-20 2018-06-20
PCT/US2018/051014 WO2019055750A1 (en) 2017-09-15 2018-09-14 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CR20200114A true CR20200114A (es) 2020-06-01

Family

ID=65723108

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200114A CR20200114A (es) 2017-09-15 2018-09-14 Compuestos que contienen pirazolopirimidinona y sus usos

Country Status (22)

Country Link
US (1) US10738056B2 (es)
EP (1) EP3681888A4 (es)
JP (1) JP2020533376A (es)
KR (1) KR20200032751A (es)
CN (1) CN111212839A (es)
AU (1) AU2018331456B2 (es)
BR (1) BR112020003676A2 (es)
CA (1) CA3075751A1 (es)
CL (1) CL2020000544A1 (es)
CO (1) CO2020002107A2 (es)
CR (1) CR20200114A (es)
DO (1) DOP2020000051A (es)
EC (1) ECSP20018586A (es)
IL (1) IL273236A (es)
JO (1) JOP20200055A1 (es)
MA (1) MA50256A (es)
MX (1) MX2020002869A (es)
PE (1) PE20210340A1 (es)
PH (1) PH12020500500A1 (es)
SG (1) SG11202002218VA (es)
TW (1) TW201920185A (es)
WO (1) WO2019055750A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
MX2020004858A (es) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso.
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
ES3055173T3 (en) * 2019-08-21 2026-02-10 Scripps Research Inst Bicyclic agonists of stimulator of interferon genes sting
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN110627725B (zh) * 2019-10-14 2022-10-18 遵义医科大学 一种4-取代5-二氟甲基-3-硝基-1h-吡唑类化合物及其制备方法与应用
US11512097B2 (en) 2019-11-25 2022-11-29 Amgen Inc. Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
CN113248491B (zh) * 2020-02-11 2022-02-25 中国科学院上海药物研究所 一类取代的吲哚脲衍生物、合成方法及其用途
JP2023525909A (ja) * 2020-05-20 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 新規マロニトリル誘導体
EP4153593A1 (en) * 2020-05-20 2023-03-29 F. Hoffmann-La Roche AG Cgas inhibiting triazolopyrimidone derivatives
CN115551837A (zh) * 2020-05-20 2022-12-30 豪夫迈·罗氏有限公司 新型丙二腈衍生物
KR20230107807A (ko) * 2020-10-14 2023-07-18 씨4 테라퓨틱스, 인코포레이티드 의료 요법을 위한 신생기질을 분해하는 트리시클릭 화합물
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
JP2024500841A (ja) * 2020-12-22 2024-01-10 ノバルティス アーゲー ｃＧＡＳと関連する病態の処置に有用なピロロ［３．２－ｂ］ピリジン誘導体
AU2021404953A1 (en) 2020-12-22 2023-06-22 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
US20240252598A1 (en) * 2021-04-13 2024-08-01 University Of Washington Designed constitutively active cyclic gmp-amp synthase as a genetically encoded stimulant of interferons
CN120530109A (zh) * 2022-12-20 2025-08-22 万特斯治疗美国公司 作为环状gmp-amp合酶抑制剂的噻二唑衍生物和其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS625362A (ja) 1985-06-30 1987-01-12 菊地　真 ハイパ−サ−ミア用加温装置
JPH02131235A (ja) 1988-11-12 1990-05-21 Fuji Photo Film Co Ltd 新規なカプラーを含有するハロゲン化銀写真感光材料
US5420128A (en) 1990-10-09 1995-05-30 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor
WO1992018504A1 (en) * 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
AU707530B2 (en) 1995-09-28 1999-07-15 Otsuka Pharmaceutical Factory, Inc. Analgesic composition
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
CA2283896A1 (en) * 1997-03-14 1998-09-24 Shintaro Ishikawa Novel pyrimidine derivative
JP3625362B2 (ja) 1997-09-08 2005-03-02 コニカミノルタホールディングス株式会社 感熱転写記録材料及び感熱転写記録方法
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
EP1511751B1 (en) 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
CA2504448C (en) 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
UY31293A1 (es) 2007-08-14 2009-03-31 Pirimidinas biciclicas fusionadas
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009071705A1 (en) * 2007-12-07 2009-06-11 Galapagos Nv Pyrazolepyrimidine compounds useful for the treatment of degenerative & inflammatory diseases
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
UA110347C2 (uk) * 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
WO2012041817A1 (en) 2010-09-27 2012-04-05 Proximagen Ltd 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as ccr2 receptor antagonists
US10953012B2 (en) * 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2864338B1 (en) 2012-05-23 2016-12-14 Savira Pharmaceuticals GmbH 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150014506A (ko) 2012-05-23 2015-02-06 사피라 파르마슈티칼즈 게엠베하 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
RU2015143517A (ru) 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
CA2922925A1 (en) * 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
EP3148986A4 (en) 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
JP6754772B2 (ja) 2015-10-23 2020-09-16 武田薬品工業株式会社 複素環化合物
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
KR102467347B1 (ko) 2016-04-15 2022-11-14 바이엘 애니멀 헬스 게엠베하 피라졸로피리미딘 유도체
WO2017210678A1 (en) 2016-06-03 2017-12-07 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CN111886225A (zh) * 2017-08-21 2020-11-03 纳维根公司 Arf6抑制剂及相关方法

Also Published As

Publication number Publication date
CL2020000544A1 (es) 2020-10-02
AU2018331456A1 (en) 2020-03-05
JOP20200055A1 (ar) 2020-03-10
IL273236A (en) 2020-04-30
PH12020500500A1 (en) 2021-03-01
CN111212839A (zh) 2020-05-29
PE20210340A1 (es) 2021-02-22
BR112020003676A2 (pt) 2020-09-01
TW201920185A (zh) 2019-06-01
DOP2020000051A (es) 2020-08-15
US10738056B2 (en) 2020-08-11
KR20200032751A (ko) 2020-03-26
US20190119285A1 (en) 2019-04-25
SG11202002218VA (en) 2020-04-29
CA3075751A1 (en) 2019-03-21
WO2019055750A1 (en) 2019-03-21
CO2020002107A2 (es) 2020-05-29
EP3681888A1 (en) 2020-07-22
MA50256A (fr) 2020-07-22
AU2018331456B2 (en) 2020-10-08
ECSP20018586A (es) 2020-06-30
EP3681888A4 (en) 2021-07-07
MX2020002869A (es) 2020-07-24
JP2020533376A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2025009223A (es) Agentes de union a clec9a y su uso
PH12015500825A1 (en) Substituted benzene compounds
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201792047A1 (ru) Новые соединения
EA201690159A1 (ru) Способы и композиции для лечения рака
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2013011922A (es) Compuestos de benceno substituido.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2018006223A (es) Moduladores de ror-gamma.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
UA119458C2 (uk) Сполуки піридину пладієноліду та способи застосування
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2019005821A (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain